-
Lovotibeglogene autotemcel, sold
under the
brand name
Lyfgenia, is a
lentiviral gene
therapy used for the
treatment of
sickle cell disease. The most common...
-
elivaldogene autotemcel (Skysona) for the
treatment of adrenoleukodystrophy.
Lyfgenia: In
December 2023, the
company received FDA
approval of lovo-cel for the...
- both
exagamglogene autotemcel (Casgevy) and
lovotibeglogene autotemcel (
Lyfgenia) were
approved for the
treatment of
sickle cell disease.
Kendric Cromer...
- maraleucel)". U.S. Food and Drug
Administration (FDA). 4
March 2021. "
Lyfgenia". U.S. Food and Drug
Administration (FDA). 8
December 2023.
Archived from...
-
Lutrepulse Kit
lutropin alfa (INN)
Luvox luxabendazole (INN)
Luxiq Luxturna Lyfgenia Lygen lymecycline (INN)
Lymepak Lymphazurin LymphoScan LymphoStat-B lynestrenol...
-
Disease (SCD). The FDA
approved two
milestone treatments,
Casgevy and
Lyfgenia,
representing the
first cell-based gene
therapies for the
treatment of...
-
vicleucel (Abecma):
treatment for
multiple myeloma Lovotibeglogene autotemcel (
Lyfgenia):
treatment for
sickle cell disease.
Nadofaragene firadenovec (Adstiladrin):...
- β-globin
genes include two cell-based gene
therapy options,
Casgevy and
Lyfgenia,
which were
approved by the FDA in 2023.
Casgevy makes use of CRISPR-Cas9...
- Abecma, and Carvykti); gene
therapies Zynteglo, Casgevy, Skysona, and
Lyfgenia; and
various other cell
therapy products (Provenge, Laviv, Gintuit, Maci...
